Stanley Laman Group Ltd. Makes New Investment in Organon & Co. (NYSE:OGN)

Stanley Laman Group Ltd. purchased a new position in Organon & Co. (NYSE:OGN) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,074 shares of the company’s stock, valued at approximately $165,000.

Other institutional investors have also modified their holdings of the company. Prospera Private Wealth LLC acquired a new position in shares of Organon & Co. in the third quarter worth $25,000. Horizon Bancorp Inc. IN grew its stake in shares of Organon & Co. by 2,401.5% in the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock worth $25,000 after acquiring an additional 1,585 shares in the last quarter. Versant Capital Management Inc grew its stake in shares of Organon & Co. by 92.2% in the fourth quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock worth $41,000 after acquiring an additional 1,324 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in shares of Organon & Co. by 32.4% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after acquiring an additional 672 shares in the last quarter. Finally, Abich Financial Wealth Management LLC grew its stake in shares of Organon & Co. by 5,646.3% in the third quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock worth $45,000 after acquiring an additional 2,315 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Performance

Shares of OGN stock opened at $16.31 on Friday. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The firm has a fifty day moving average price of $15.34 and a 200 day moving average price of $17.53. The company has a market cap of $4.20 billion, a P/E ratio of 3.24, a PEG ratio of 0.83 and a beta of 0.76. Organon & Co. has a 12 month low of $13.87 and a 12 month high of $23.10.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. Sell-side analysts predict that Organon & Co. will post 3.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $21.33.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.